Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Li
Post# of 721
(Total Views: 262)
Posted On: 05/14/2018 5:08:36 PM
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Licensing Agreement Renewal with Nuka Enterprises Reinforces DehydraTECH™ Revenue Strategy
- Report: LXRP is a ‘compelling investment opportunity’ which is creating recurring licensing revenue that unlocks shareholder value
- LXRP’s DehydraTECH is a patented delivery technology platform that is renewal-licensed by Nuka in a 10-year semi-exclusive agreement that expands its reach into Canada
- Company is growing its patent portfolio for proprietary DehydraTECH; it already has patents granted in Australia and the U.S. and has patents pending in more than 40 countries worldwide
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) renewal of its DehydraTECH™ license with Nuka Enterprises LLC could help make it a compelling investment opportunity in the cannabis industry as its licensing and royalties from that technology platform deliver recurring revenue that could unlock significant value for its shareholders, according to an article by CFN Media Group (http://nnw.fm/FU1Ar).
Chris Bunka, CEO of LXRP, estimated in an audio interview that up to 80 percent of Lexaria’s revenues are generated through the licensing of its proprietary technology to other companies (http://nnw.fm/Uup5f). CFN wrote that the Nuka license renewal “represents a strong vote of confidence in the technology.”
LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. It out-licenses its disruptive delivery technology that promotes healthier ingestion methods and lower overall dosing. It has developed the patented DehydraTECH delivery technology platform.
Nuka Enterprises markets the 1906 brand of cannabis chocolates using LXRP’s technology. It has been using LXRP’s platform for almost two years, when it first entered the cannabis market. The renewal enables Nuka to market across the U.S. It also has an option that permits the company to expand into Canada with the brand through the use of LXRP’s existing contract manufacturer of chocolates and confections licensee, Cannfections Group Inc. (http://nnw.fm/ZyJ2C).
Nuka has indicated that it will initially focus on the U.S. states that permit recreational and adult-use of cannabis, such as Colorado, Nevada, California, New Jersey and Massachusetts. Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, generating more revenue for the company and building greater shareholder value.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Report: LXRP is a ‘compelling investment opportunity’ which is creating recurring licensing revenue that unlocks shareholder value
- LXRP’s DehydraTECH is a patented delivery technology platform that is renewal-licensed by Nuka in a 10-year semi-exclusive agreement that expands its reach into Canada
- Company is growing its patent portfolio for proprietary DehydraTECH; it already has patents granted in Australia and the U.S. and has patents pending in more than 40 countries worldwide
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) renewal of its DehydraTECH™ license with Nuka Enterprises LLC could help make it a compelling investment opportunity in the cannabis industry as its licensing and royalties from that technology platform deliver recurring revenue that could unlock significant value for its shareholders, according to an article by CFN Media Group (http://nnw.fm/FU1Ar).
Chris Bunka, CEO of LXRP, estimated in an audio interview that up to 80 percent of Lexaria’s revenues are generated through the licensing of its proprietary technology to other companies (http://nnw.fm/Uup5f). CFN wrote that the Nuka license renewal “represents a strong vote of confidence in the technology.”
LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. It out-licenses its disruptive delivery technology that promotes healthier ingestion methods and lower overall dosing. It has developed the patented DehydraTECH delivery technology platform.
Nuka Enterprises markets the 1906 brand of cannabis chocolates using LXRP’s technology. It has been using LXRP’s platform for almost two years, when it first entered the cannabis market. The renewal enables Nuka to market across the U.S. It also has an option that permits the company to expand into Canada with the brand through the use of LXRP’s existing contract manufacturer of chocolates and confections licensee, Cannfections Group Inc. (http://nnw.fm/ZyJ2C).
Nuka has indicated that it will initially focus on the U.S. states that permit recreational and adult-use of cannabis, such as Colorado, Nevada, California, New Jersey and Massachusetts. Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, generating more revenue for the company and building greater shareholder value.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼